1. Home
  2. TGTX vs TRNO Comparison

TGTX vs TRNO Comparison

Compare TGTX & TRNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$30.74

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Logo Terreno Realty Corporation

TRNO

Terreno Realty Corporation

HOLD

Current Price

$62.40

Market Cap

6.0B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
TGTX
TRNO
Founded
1993
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
5.5B
6.0B
IPO Year
1995
2010

Fundamental Metrics

Financial Performance
Metric
TGTX
TRNO
Price
$30.74
$62.40
Analyst Decision
Strong Buy
Buy
Analyst Count
5
12
Target Price
$51.60
$65.58
AVG Volume (30 Days)
2.4M
617.8K
Earning Date
03-02-2026
02-04-2026
Dividend Yield
N/A
3.32%
EPS Growth
N/A
75.67
EPS
2.78
3.15
Revenue
$531,898,000.00
$442,611,000.00
Revenue This Year
$87.88
$23.60
Revenue Next Year
$47.78
$7.96
P/E Ratio
$11.01
$19.92
Revenue Growth
100.88
21.13
52 Week Low
$25.28
$48.18
52 Week High
$46.48
$69.20

Technical Indicators

Market Signals
Indicator
TGTX
TRNO
Relative Strength Index (RSI) 53.06 67.22
Support Level $26.89 $58.77
Resistance Level $33.24 $60.45
Average True Range (ATR) 1.56 1.17
MACD 0.14 0.33
Stochastic Oscillator 60.55 93.72

Price Performance

Historical Comparison
TGTX
TRNO

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

About TRNO Terreno Realty Corporation

Terreno Realty Corp is a real estate investment trust engaged in acquiring, owning, and operating industrial real estate in six coastal U.S. markets: Los Angeles, Northern New Jersey/New York City, San Francisco Bay Area, Seattle, Miami, and Washington, D.C. The company invests in several types of industrial real estate, including warehouse/distribution, flex (including light industrial and research and development), transshipment, and improved land.

Share on Social Networks: